5-MeO-DALT

Use and effects

According to Alexander Shulgin in a follow-up entry to his book TiHKAL (Tryptamines I Have Known and Loved), the dose of 5-MeO-DALT is 12 to 20mg orally and its duration is 2 to 4hours. A wider dose range of 12 to 25mg has also been reported. It is said to onset and peak remarkably quickly via the oral route, with an onset of less than 15minutes and a time to peak of 30minutes. The effects of 5-MeO-DALT were reported by Shulgin to include positive emotional changes, lightheadedness, increased appreciation of music and sex, and closed-eye visuals. There was said to be a lack of open-eye visuals and it was said to be relatively light in psychedelic character.

Overdose

There is little published literature on the toxicity of 5-MeO-DALT. Case reports of overdose have been published, with effects including loss of consciousness, visual hallucinations, acute delirium, and rhabdomyolysis, among others. A death related to behavioral intoxication has been reported.

Interactions

Pharmacology

Pharmacodynamics

The interactions of 5-MeO-DALT with various targets have been reported. It binds to a variety of serotonin receptors, as well as a number of other targets. The drug is a potent full agonist of the serotonin 5-HT1A and 5-HT2A receptors. It is also an agonist of the serotonin 5-HT2B and 5-HT2C receptors.

Uniquely the substance displayed weak agonist-like activity at the μ-opioid (MOR) and δ-opioid receptors (DOR) along with more significant activity at the κ-opioid receptor (KOR) (∼76% of salvinorin A at 1 μM concentration) with G protein bias over β-arrestin activation.

Similarly to other psychedelics, 5-MeO-DALT produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. The drug fully substitutes for the serotonergic psychedelic DOM in rodent drug discrimination tests. Conversely, 5-MeO-DALT does not substitute for the entactogen MDMA in such tests. 5-MeO-DALT produces dose-dependent hyperlocomotion in rodents, followed by hypolocomotion at the highest assessed dose. This is in contrast to many other psychedelic tryptamines, which tend to produce only hypolocomotion. 5-MeO-DMT and 5-MeO-AMT are locomotor depressants, whereas 5-MeO-DET and 5-MeO-MiPT are mixed locomotor stimulants/depressants similarly to 5-MeO-DALT. It also produces hypothermia.

The head-twitch response induced by 5-MeO-DALT in rodents was found to be positively related to its serotonin 5-HT2A receptor affinity and negatively related to its serotonin 5-HT1A receptor affinity. In relation to this, multiple targets appear to contribute to the effects of 5-MeO-DALT.

Pharmacokinetics

The metabolism and cytochrome P450 inhibition of 5-MeO-DALT has been described in scientific literature.

Chemistry

The full name of the chemical is N-allyl-N-2-(5-[methoxy-1H-indol-3-yl)ethyl] prop-2-en-1- amine. It is related to the compounds 5-MeO-DPT, DALT, 4-HO-DALT, and 4-AcO-DALT.

Synthesis

The chemical synthesis of 5-MeO-DALT has been described.

Crystal structure

In April 2020, Chadeayne et al. solved the crystal structure of the freebase form of 5-MeO-DALT.

Analogues

Analogues of 5-MeO-DALT include diallyltryptamine (DALT), 4-HO-DALT (daltocin), 4-AcO-DALT (dalcetin), NB-5-MeO-DALT, 5-MeO-DMT, 5-MeO-DET, 5-MeO-DPT, 5-MeO-DiPT, 5-MeO-MALT, 5-MeO-MiPT, and 5-MeO-iPALT (ASR-3001), among others.

History

The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a research associate named Murple in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet research chemical vendors after being synthesized by commercial laboratories in China. In August 2004 the synthesis and effects of 5-MeO-DALT were published by Erowid. Shulgin has stated that 5-MeO-DALT had not previously existed in the scientific literature. 5-MeO-DALT was not included in the original published version of TiHKAL, but an entry for the compound was subsequently written and released in 2004. The drug was encountered as a novel designer drug by at least 2006.

Society and culture

Legal status

Canada

5-MeO-DALT is not a controlled substance in Canada as of 2025.

China

As of October 2015 5-MeO-DALT is a controlled substance in China.

Japan

5-MeO-DALT became a controlled substance in Japan from April 2007, by amendment to the Pharmaceutical Affairs Law.

Singapore

5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.

Sweden

Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.

United Kingdom

5-MeO-DALT became a Class A drug in the UK on January 7, 2015 after an update to the tryptamine blanket ban.

United States

5-MeO-DALT is not scheduled at the federal level in the United States, but it is likely that it could be considered an analog of 5-Meo-DiPT, which is a controlled substance in USA, or an analog of another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.

Florida

5-MeO-DALT is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.

Louisiana

5-MeO-DALT is a Schedule I controlled substance in the state of Louisiana making it illegal to buy, sell, or possess in Louisiana.

Research

Cluster headache

Anecdotal reports and a small-scale trial indicate the potential of 5-MeO-DALT for the treatment of cluster headache, one of the most excruciating conditions known to medicine. These observations are consistent with evidence of efficacy of other chemically-related indoleamines in the treatment of cluster headache.

References

References

1. Anvisa. (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (December 2012). "The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review". Prog Neuropsychopharmacol Biol Psychiatry.
3. (2018). "Chemistry and Structure-Activity Relationships of Psychedelics".
4. "5-MeO-DALT".
5. "#56 5-MeO-DALT".
6. "Sasha Shulgin - 5-MeO-DALT, 2C-B-FLY & 5-EtOs".
7. (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology.
8. (August 2022). "Loss of Consciousness and Visual Hallucinations Related to 5-MeO-DALT Intake, a Case Report Confirmed by Toxicological Analyses". J Anal Toxicol.
9. (October 2016). "5-MeO-DALT; a novel designer drug on the market causing acute delirium and rhabdomyolysis". Acta Anaesthesiol Scand.
10. (May 2014). "Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT". J Forensic Sci.
11. (28 March 2025). "Kᵢ Database".
12. Liu, Tiqing. "BindingDB BDBM50435344 CHEMBL2391541".
13. (February 2016). "Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines". Bioorganic & Medicinal Chemistry Letters.
14. (November 2018). "Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs". Neuropharmacology.
15. (August 2024). "Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties". Mol Psychiatry.
16. (June 2013). "An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'". Bioorg Med Chem Lett.
17. (April 2023). "Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter". J Pharmacol Exp Ther.
18. (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". Eur J Pharmacol.
19. (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice". ACS Chem Neurosci.
20. (December 2024). "Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice". ACS Chem Neurosci.
21. (December 2019). "Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances". Anal Chem.
22. (August 2017). "Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents". Behav Pharmacol.
23. (October 2015). "Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS". Springer Science and Business Media LLC.
24. (January 2016). "Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class". Elsevier BV.
25. (November 2022). "In Vitro Metabolite Identification Studies for the New Psychoactive Substances Furanylfentanyl, TFMPP, and 5-MeO-DALT in Human Liver Microsomes". Current Analytical Chemistry.
26. (April 2020). "5-MeO-DALT: the freebase of ''N'',''N''-diallyl-5-meth-oxy-tryptamine". International Union of Crystallography (IUCr).
27. (2010-05-02). "The Last Interview With Alexander Shulgin".
28. "Controlled Drugs and Substances Act".
29. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
30. "厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について".
31. (30 April 2015). "CNB NEWS RELEASE". Central Narcotics Bureau (CNB).
32. (20 April 2012). "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika".
33. "§1308.11 Schedule I.".
34. "Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL". Florida Statutes.
35. "Louisiana State Legislature".
36. (2015). "Cluster Headache Patient Survey: 5-MeO-DALT". Figshare.
37. (2014). "Treatment of Cluster Headache Symptoms using Synthetic Tryptamine N,N-Diallyl-5 Methoxytryptamine". Figshare.
38. (February 2020). "Pharmacotherapy for Cluster Headache". Springer Science and Business Media LLC.
39. (2015-10-20). "Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey". Informa UK Limited.